EpiCast Report: Multiple Sclerosis - Epidemiology Forecast to 2023

Date: May 15, 2014
Pages: 61
Price:
US$ 3,995.00
License [?]:
Publisher: GlobalData
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: E8330B4A44FEN
Leaflet:

Download PDF Leaflet

EpiCast Report: Multiple Sclerosis - Epidemiology Forecast to 2023
EpiCast Report: Multiple Sclerosis - Epidemiology Forecast to 2023

Summary

Multiple sclerosis (MS) is an inflammatory disease in which the myelin sheaths around the axons of the brain and spinal cord are damaged, leading to demyelination and a wide range of signs and symptoms. MS affects 2.5 million people worldwide each year and is the most debilitating neurological disease in young adults.

GlobalData epidemiologists expect that the number of prevalent and incident cases of MS will increase during the forecast period (2013-2023) in the 10MM. In 2013, GlobalData epidemiologists forecast that there were a total of 904,908 prevalent cases of MS in the 10MM, and by 2023 GlobalData epidemiologists forecast that the number of prevalent cases will grow to 940,413 prevalent cases. During the forecast period, India will have the highest annual growth rate (AGR) at 1.99%, Spain will have the second highest (AGR: 1.05%), and China will have the third highest (AGR: 0.93%).

GlobalData epidemiologists used country-specific sources published by peer-reviewed journals to estimate the incidence and prevalence of MS in each of the 10MM. To provide a thorough description of the MS patient population in each country, GlobalData epidemiologists segmented MS incident and prevalent cases by age and sex, both of which strongly affect the epidemiology of MS. Moreover, cases are segmented into three common sub-types: relapsing-remitting MS, primary progressive MS, and secondary progressive MS. A major strength of this analysis is that the forecast methodology was consistent across the 10MM to allow for a meaningful comparison of the patient populations in each country.

Scope
  • The Multiple Sclerosis (MS) EpiCast Report provides an overview of the risk factors and comorbidities, and global and historical trends of MS in the 10 major markets (10MM) (the US, France, Germany, Italy, Spain, the UK, Japan, Canada, China and India). It includes a 10-year epidemiological forecast of MS prevalent and incident cases segmented by sex and age (in five-year increments beginning at 20 years and ending at =85 years) in these markets.
  • The MS epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
  • The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 10MM.
Reasons to buy
  • Develop business strategies by understanding the trends shaping and driving the global MS market.
  • Quantify patient populations in the global MS market to improve product design, pricing, and launch plans.
  • Organize sales and marketing efforts by identifying the sex and age groups that present the best opportunities for MS therapeutics in each of the markets covered.
1 TABLE OF CONTENTS

1.1 List of Tables
1.2 List of Figures

2 INTRODUCTION

2.1 Catalyst
2.2 Upcoming Reports

3 EPIDEMIOLOGY

3.1 Disease Background
3.2 Risk Factors
  3.2.1 Family members of MS patients have a 1%-5% risk of developing MS
  3.2.2 Women are twice as likely to develop MS, but men have a worse prognosis
  3.2.3 Caucasians have a higher risk of MS than any other race/ethnicity
  3.2.4 Protective effect of vitamin D on MS may relate to latitude and month of birth
  3.2.5 Timing of environmental exposures affects MS risk
  3.2.6 Exposure to smoking may increase MS risk and worsen prognosis
3.3 Comorbidities
  3.3.1 Autoimmune diseases may be comorbidities of MS
  3.3.2 Mental comorbidities are found in up to 60% of MS patients and may affect relapse rates
3.4 Global Trends
  3.4.1 North America
  3.4.2 Europe
  3.4.3 Asia
3.5 Forecast Methodology
  3.5.1 Sources Used
  3.5.2 Sources Not Used
  3.5.3 Forecast Assumptions and Methods
3.6 Epidemiological Forecast of Multiple Sclerosis (2013-2023)
  3.6.1 Total Prevalent Cases of Multiple Sclerosis
  3.6.2 Age-Specific Prevalent Cases of Multiple Sclerosis
  3.6.3 Sex-Specific Prevalent Cases of Multiple Sclerosis
  3.6.4 Total Incident Cases of Multiple Sclerosis
  3.6.5 Age-Specific Incident Cases of Multiple Sclerosis
  3.6.6 Sex-Specific Incident Cases of Multiple Sclerosis
  3.6.7 Multiple Sclerosis Subtypes
3.7 Discussion
  3.7.1 Epidemiological Forecast Insight
  3.7.2 Limitations of the Analysis
  3.7.3 Strengths of the Analysis

4 APPENDIX

4.1 Bibliography
4.2 About the Authors
  4.2.1 Epidemiologists
  4.2.2 Reviewers
  4.2.3 Global Director of Epidemiology
  4.2.4 Global Head of Healthcare
4.3 About GlobalData
4.4 About EpiCast
4.5 Disclaimer

LIST OF TABLES

Table 1: Sources of Prevalence and Incidence Data Used in the Epidemiology Forecast
Table 2: 10MM, Prevalent Cases of MS, Ages ≥20 Years, Men and Women, N, Select Years, 2013-2023
Table 3: 10MM, Prevalent Cases of MS, By Age, Men and Women, N (Row %), 2013
Table 4: 10MM, Prevalent Cases of MS, Ages ≥20 Years, By Sex, N (Row %), 2013
Table 5: 10MM, Incident Cases of MS, Ages ≥20 Years, Men and Women, N, Select Years, 2013-2023
Table 6: 10MM, Incident Cases of MS, By Age, Men and Women, N (Row %), 2013
Table 7: 10MM, Incident Cases of MS, By Sex, N (Row %), 2013

LIST OF FIGURES

Figure 1: 10MM, Prevalent Cases of MS, Ages ≥20 Years, Men and Women, N, Select Years, 2013-2023
Figure 2: 10MM, Prevalent Cases of MS, By Age, Men and Women, N, 2013
Figure 3: 10MM, Prevalent Cases of MS, Ages ≥20 Years, By Sex, N, 2013
Figure 4: 10MM, Incident Cases of MS, Ages ≥20 Years, Men and Women, N, Select Years, 2013-2023
Figure 5: 10MM, Incident Cases of MS, By Age, Men and Women, N, 2013
Figure 6: 10MM, Incident Cases of MS, By Sex, N, 2013
Figure 7: 10MM, MS Subtype Distributions, %, 2013-2023

Ask Your Question

EpiCast Report: Multiple Sclerosis - Epidemiology Forecast to 2023
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry: